Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALPL | P05186 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853023 | 0.86 | SMN1; SMN2 (0.66) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13629773 | 0.85 | ALDH1A1 (0.57) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13615080 | 0.82 | ALDH1A1 (0.77) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18530465 | 0.82 | SMN1; SMN2 (0.79) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13629552 | 0.82 | PKM (0.74) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL13629345 | 0.79 | PGR (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL7531220 | 0.78 | TP53 (0.71) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7529463 | 0.78 | TP53 (0.80) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5962533 | 0.78 | SMN1; SMN2 (0.71) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7535714 | 0.78 | SMN1; SMN2 (0.72) | ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | ALDH1A1 2121/4885NPSR1 4042/4885SMN1; SMN2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.